Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma.
Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumberso
Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review.
England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.